drugset / Trial / NCT02084953

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

NCT02084953

Phase 1 Completed 59 enrolled Bristol-Myers Squibb
RandomizedCrossoverQuadruple-blind

Summary

The purpose of this study is to determine whether BMS-791325 has an effect on the electrocardiogram (ECG) interval QT corrected for Fridericia's method (QTcF).

Timeline

Start
2014-04
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Beclabuvir Small molecule 900 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral